Nanoneuromedicine for management of neurodegenerative disorder by Dwivedi, Nitin et al.
Manuscript Details
Manuscript number JDDST_2018_1318_R1
Title Nanoneuromedicine for management of neurodegenerative disorder
Short title Nanoneuromedicine
Article type Review Article
Abstract
Conventional drug delivery systems are inadequate in providing essential cyto-architecture restoration and connection
patterns because of restrictions posed by the restrictive blood-brain barrier. Nanotechnological approaches involve
various nano-sized carrier systems and other devices, which stimulate the action of therapeutic agents on molecular
level and revolutionized the treatment and diagnosis of neurodegenerative disorders with minimal side effects. Over
the conventional approaches, nanotechnological approaches have various promising strategies to cross blood brain
barrier and increase the bioavailability of therapeutics in brain. This review article emphasizes the current and future
utility of nano drug delivery systems for the treatment of various neurodegenerative disorders.
Keywords Neurodegenerative disorder; Parkinson disease; Nanotechnology; Alzheimer
Corresponding Author Prashant Kesharwani
Corresponding Author's
Institution
SAAD Centre for Pharmacy and Diabetes, School of Pharmacy and
Pharmaceutical Science, Ulster University
Order of Authors Nitin Dwivedi, Jigna Shah, Vijay Mishra, Murtaza Tambuwala, Prashant
Kesharwani
Suggested reviewers Chitra Thakur, Bapi Gorain, V.R. Sinha, MOHD CAIRUL IQBAL MOHD AMIN
Submission Files Included in this PDF
File Name [File Type]
1_Cover Letter.docx [Cover Letter]
2_Response to reviewers.docx [Response to Reviewers]
3_Manuscript with changed marked.docx [Revised Manuscript with Changes Marked]
3_GA.docx [Graphical Abstract]
3_Manuscript.docx [Manuscript File]
To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE
Homepage, then click 'Download zip file'.
Ref: JDDST_2018_1318
Title: Nanoneuromedicine: An effective vista for management of neurodegenerative disorder
Journal: Journal of Drug Delivery Science and Technology
To,
Professor Repka
Associate Editor
Journal of Drug Delivery Science and Technology
Subject: Regarding submission of revised manuscript entitled “Nanoneuromedicine: An 
effective vista for management of neurodegenerative disorder”
Dear Prof. Repka,
With reference to your e-mail dated 3rd December 2018, we are happy to hear that our 
manuscript has been reviewed by potential reviewers and they concluded to accept our paper 
subjected to minor revisions. As per reviewer suggestions, we have cautiously gone through 
the comments regarding required changes in the manuscript (please see “Response to 
reviewers” file for details). We have thoroughly revised the manuscript by “highlighted text” 
to address reviewers’ concerns. Hope you will find revised manuscript suitable for publication.
Thanking you in anticipation and a favorable response.
Kindly acknowledge
Best Regards,
Best Regards,
Dr. Prashant Kesharwani (M. Pharm., PhD)
Pharmaceutics and Pharmacokinetics Division
CSIR-Central Drug Research Institute
Sector-10, Jankipuram Extension
Lucknow, 226031, U.P., India
E-mail: prashantdops@gmail.com; prashant_pharmacy04@rediffmail.com
Tel: +91-7999710141            Skype ID: prashantdops
https://scholar.google.com/citations?user=DJkvOAQAAAAJ&hl=en
Reply to the Reviewer’s Comments
REVIEWER 1: This is a very interesting review article that provides new insight on the management 
of neurodegenerative disorder. It provides latest update on the treatment of many related diseases from 
the perspective of nano medicine for example Alzheimer's Disease. Clear and concise explanation are 
provided which helps many readers will find this article meaningful especially for those who are new in 
this area. This review article also provides some critical opinion on the future of such treatment and 
predicted what it would be like in the near future. Apart from a few grammatical and spelling errors, this 
article is acceptable. 
REPLY: We would like to thank the honored reviewer for their encouraging comments and their 
positive recommendation for the acceptance of the manuscript. As per the suggestion, the 
manuscript has been revised in relation to the English language with due assistance from a 
native English speaker.
REVIEWER 2:
COMMENT 1: The article written by Dwivedi et al. focuses on the nanoneuromedicine for management 
of neurodegenerative disorder. Authors extensively investigated the recent activities in this research 
field and described the merit of nanotechnology as potential approach to overcome neurodegenerative 
disorders. The exhaustive information would be helpful for the researchers in this research field. From 
these merits, I could recommend publication of this manuscript after following minor changes:
REPLY: We would like to thank the honored reviewer for their encouraging comments and their 
positive recommendation for the acceptance of the manuscript. As per the suggestion, the 
manuscript has been revised.
1. Revise title as “Nanoneuromedicine for management of neurodegenerative disorder”
REPLY: Complied.
2. References are rich but are not updated well. Please add few more relevant references of 2018.
REPLY: Complied; 6 new references has been as added as suggested (Ref.# 4,7,9,12,21,22).
3. Revise the abstract to make it more informative.
REPLY: Complied.
4. Figure 1 caption looks incomplete. Revise it.
REPLY: Complied.
*************************
1Nanoneuromedicine for management of neurodegenerative disorder
Nitin Dwivedi,a Jigna Shah,a Vijay Mishra,b Murtaza Tambuwalac, Prashant 
Kesharwanid* #
a Pharmacology Research Laboratory, Institute of Pharmacy, Nirma University, Ahmedabad,
Gujarat, 382481, India.
b School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 
144411, India
c School of Pharmacy and Pharmaceutical Sciences, Saad Centre for Pharmacy and 
Diabetes, Ulster University, Cromore Road, Coleraine, Co. Londonderry BT52 1SA, United 
Kingdom
d Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, 
Lucknow, 226031, U.P., India
# Current address: Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug 
Research Institute, Lucknow, 226031, U.P., India
*Address for correspondence:
Dr. Prashant Kesharwani (M. Pharm., PhD)
Pharmaceutics and Pharmacokinetics Division, 
CSIR-Central Drug Research Institute, 
Lucknow, 226031, U.P., India
Email: prashantdops@gmail.com; Prashant_pharmacy04@rediffmail.com  
Tel / Fax:  +91-7999710141
Disclosures: There is no conflict of interest and disclosures associated with the manuscript.
2Abstract:
Conventional drug delivery systems are inadequate in providing essential cyto-architecture 
restoration and connection patterns because of restrictions posed by the restrictive blood-
brain barrier. Nanotechnological approaches involve various nano-sized carrier systems and 
other devices, which stimulate the action of therapeutic agents on molecular level and 
revolutionized the treatment and diagnosis of neurodegenerative disorders with minimal side 
effects. Over the conventional approaches, nanotechnological approaches have various 
promising strategies to cross blood brain barrier and increase the bioavailability of 
therapeutics in brain. This review article emphasizes the current and future utility of nano 
drug delivery systems for the treatment of various neurodegenerative disorders.
Keywords: Neurodegenerative disorder; Parkinson disease; Nanotechnology; Alzheimer.
31. Introduction
Neurodegenerative disorders (NDs) inscribe the progressive damage of neurons, 
usually concerned with death of neuronal cells. Various types of NDs like Alzheimer's (AD), 
Parkinson's (PD), Prion (PrD) disease and Amyotrophic Lateral Sclerosis (ALS) are 
associated with the neuronal damage in the different areas of brain and spinal cord. At present 
the available diagnosis and treatment strategies for NDs are inadequate to inhibit the 
progression of the brain injury or degeneration. The blood-brain barrier (BBB) appeared as  
one of the most arduous hurdles for the transport of therapeutic or imaging contrast agent into 
the nervous system [1–4]. While the available potentials for imaging and therapy of brain 
disorders mostly depend on the vascular and penetration ability across the BBB [5–7], for the 
rectification of these problems, a novel, safe and more sensitive imaging modality with 
improved therapeutic potential is immediately required. The nanoneuro-medicine offer 
innovative and promising approaches to address the NDs as well as other nervous system 
diseases for which limited options are available [8].
Theranostics, the nanotechnology-based devices, have ability to deliver therapeutic, 
imaging and diagnostic agents at a time [9]. However current practices of nanotechnology in 
pharmaceutical field have been represented in Figure 1A & 1B. Nanomedicine and other 
related technologies improve transportation of biological active/imaging/contrast agents from 
the BBB; increase the drug-carrier bond with clearance of pathogens from nervous system 
[10]. At present various types of nanomaterials are available with different physicochemical 
and therapeutic properties. The nanomedicines have tremendous positive features like greater 
chemical or biological substantiality, incorporating capability for hydrophilic as well as 
hydrophobic molecules, can be used in the treatment or diagnosis of various NDs (Table 1). 
In addition, the nanomedicines can administer from several routes like olfactory, oral and 
4systemic etc. This review highlights variety of features of nano technological approaches 
involved in the treatment and prognosis of various NDs.
1.1 Latest developments in nanotechnology, nanomaterials and nanoarchitectonics
Recently, in the field of nanomedicine Li et al. developed layer-by-layer self-
assembled stacked Testudo-like MoS2-NS superstructures carrying doxorubicin (Dox) and 
DNA oligonucleotides, which was considered as a base platform, achieving high efficacy and 
autonomous ATP responsive drug delivery [11,12].
Single walled carbon nanohorns (CNHs) are graphene-based tubules having 25 nm 
diameter and 4050 nm length. In medical field, their potential uses are in drug delivery, 
diagnosis, and clinical tests. Nakamura et al. developed micelles based drug delivery system 
by dispersing CNH in phospholipid poly(ethylene glycol) (PLPEG) and revealed the effect of 
PLPEG quantity on the cytotoxicity of PLPEG-CNH in RAW264.7 mouse macrophages. The 
optimum PLPEG:CNH weight ratio was found to be 0.5:1 and 1:1. At the higher or lower 
ratios, the PLPEG-CNH toxicity and the macrophage uptake quantity increased and large 
agglomerates appeared [13]. 
Carbon nanotubes (CNTs), one of the emerging members of carbon family are 
potentially used in sensing, bone scaffolds, drug and gene delivery, composite materials, and 
water purification. The credit for successful applications of CNTs goes to desired 
conductivity, specificity, selectivity, high aspect ratio, high porosity and loading, ease in 
surface modification, and non-toxicity [14]. 
Radioisotopes are frequently used for various medical applications. Nowadays, a 
considerable quantity of 99mTc is generated in hospital using 99Mo/99mTc generators. In this 
regard, Saptiama et al. prepared mesoporous alumina (MA) materials as potential adsorbents 
for molybdenum (Mo) using a soft-templated method. The change in calcination temperature 
from 600 to 900 °C improved the crystallinity but decreased the surface area and the pore 
5volume of the MA materials. These results can guide the design of effective Mo adsorbents 
based on mesoporous materials toward 99Mo/99mTc generator preparation[15].
Nanoarchitectonics involves architecting of materials in the nanoscale. There are two 
types of bio-related nanoarchitectonics i.e. DNA nanoarchitectonics and cell macromolecular 
nanoarchitectonics. The former involves functionalization of single DNAs by chemical 
method to achieve stronger DNA binding, DNA aptamers and DNAzymes. Programmable 
assemblies of DNAs find their applications for selective labeling of biomaterials in cells and 
in animals, delivery of drugs to target sites and sensing in vivo. The later involves the 
construction of highly organized synthetic/natural macromolecular modified hybrid 
biointerfaces [16,17].
2. Nanotechnology across the BBB
The BBB is a physical and biological occlusion present in amid of central nervous 
system (CNS) and systemic blood circulation, protects brain from unwanted substances and 
other intruders [18]. The BBB contains endothelial cells, smooth muscle cells, pericytes, 
microglial cells and astrocytes with a tight junction amongst them and restrict the 
transcellular flux (Figure 2A) [19–21]. Currently, nanotechnology appears as promising 
strategy in which the nanomaterials interact with BBB at molecular level and transport across 
the BBB through existing mechanisms (Figure 2B) [20,22], without any intervention in the 
usual function of BBB and itself [23]. The nanomaterials have transcellular movement from 
blood to brain across the BBB with transcytosis movement involve receptor as well as 
adsorption mediated mechanism [24]. To achieve brain targeting across the BBB, the 
nanomaterials must have many competencies like minimum surface area, prolonged half-life 
in blood, nontoxic, biodegradable, biocompatibility, non-inflammatory and non-
immunogenic with avoidance of reticulo-endothelial system (Table 2) [25–29]. The vital 
features of nanomaterials are depicted in Figure 3.
62.1. Adsorptive-mediated transcytosis
Adsorptive-mediated transcytosis lead to electrostatic interaction of a ligand with the 
luminal surface charges of endothelial cells. The fabrication cell penetration peptides (e.g. 
TAT-derived peptides) and cationic proteins (e.g. albumin) on the surface of nanomaterials 
facilitate the passage across the BBB [24,30]. Thus, the addition of different domains like 
glycosylation [31], methylation [32] PEGylation [33–38], lipophilic domains [39,40], virus 
glycoprotein [41,42] or coating with polysorbates [24] on the surface of different types of 
nano devices lead to an enhanced penetration potential across the BBB. The diffusivity of 
nano devices across the BBB, several times depends on the material used in the coating, 
charge of the surface and the matrix of these particulate systems. An albumin coating, reduce 
the interaction between extracellular space proteins and decrease the size effect on the 
distribution of nanospheres [40,43]. Thus, these nanocarriers have greater optimization in 
convection enhanced delivery (CED) [42,44].
2.2. Receptor-mediated transcytosis
Receptor mediated transcytosis is more intensively explored physiological procedure. 
This involves the transportation of various nanomaterials across the BBB based on affinity 
towards the receptors of BBB cells. Receptor mediated transcytosis is achieved by addition of 
some specific proteins such as insulin [45], transferrin [46], apolipoprotein [47,48], macro-
globins and other small peptides that are able to act as ligands for the receptors located on 
cells of BBB.  
Certain monoclonal antibodies (mAbs) undergo receptor mediated transcytosis and 
are directed towards the receptors on BBB. Like the binding of OX26,8D3 & R17217 mAbs 
with transferrin, receptors recognize different epitopes and avert the competition with innate 
transferrin in blood [49]. On the other hand, some mAbs involved in construction of brain 
targeted drug delivery devices are directed against insulin receptors [50].
73. Nanotechnology for AD
Literature suggests that AD affects more than 24 million people worldwide. 
Alzheimer’s disease lead to onward loss or deterioration of neurons of cortical and 
hippocampal leads to memory and cognitive dysfunction [51]. Another neuropathological 
hallmark of AD is appearance of neurofibrillary tangles containing hyper-phosphorylated tau 
protein on intraneuronal paired helical filaments and extracellular plaques of β amyloid 
peptide (Aβ). Aβ are small fragments of amyloid precursor proteins (APP) containing 39-43 
amino acids. Thus, the aggregation of small segments of Aβ (ADDLs, amyloid-β-derived 
diffusible ligands) are mainly responsible for memory deficits and synaptic damage in AD 
[52,53].
3.1. AD therapy
At present, the available therapies of AD are based on cholinergic progress, 
particularly on the cholinesterase (AChE and BChE) activities prohibition [54]. Although 
cholinergic inhibitors have greatest benefit for cognitive dysfunction, these are unable to 
compensate the continuous loss of hippocampal and cortical neurons. Currently the treatment 
of AD depends on acetylcholinesterase  (AChE) inhibitors (Rivastigmine, Dopenezil, 
Galantamine) or NMDAR inhibitor (Memantine) indicate only momentary effect but unable 
to stop  disease progress and mainly administered orally or transdermally [55–57].
In year 2000, Rivastigmine, a non-competitive and reversible AChE inhibitor was 
approved by the FDA for the treatment of AD [58]. Now a day, nanotechnological strategies 
are employed for enhancing the potency of AD therapies (Figure 4). The nanotechnological 
devices target to Aβ aggregation and fragmentation of APP, not only in CNS even in blood 
with the approach of reducing its level in brain[59].The reduction of Aβ aggregation and 
fragmentation of APP in the brain is known as ‘sink effect’. Gobbi et al. developed 
nanoliposomes (NLs) utilizing phosphatidic acid or cardiolipin [60]. In an another study it 
8has been observed that these NLs have greater affinity towards Aβ and diminished the 
toxicity of these peptides in ex-vivo condition [61]. Canovi et al. developed NL formulation 
with anti-Aβ mAb, indicating higher affinity for Aβ in ex-vivo as well as in vivo studies [62]. 
In addition to these, Mourtas et al. developed another formulation of NL with curcumin 
derivative, which displayed high affinity towards Aβ and inhibited Aβ aggregation in an in 
vitro model [63,64].
Amyloid fibrillar deposition of misfolded proteins can be exploited for both therapy 
and diagnosis of AD. Recently, Orteca et al. developed structurally modified curcumin 
(phtalimmide derivative, K2F21) scaffold for improving its bioavailability, pharmacokinetic 
stability in physiological conditions, and in vitro ability to interfere with β-amyloid fibrils 
and aggregates at different incubation time. Computational simulations established the 
modification in conformational dynamics and interaction with the amyloidogenic region of 
the protofibril facilitating disaggregation on ligand binding. In vitro results reflected safety 
and protection against glutamate toxicity in hippocampal HT-22 mouse cells at 1 μM 
concentration. Authors claimed that the developed derivative of curcumin appeared as a 
promising candidate for both diagnosis and therapy of AD [65].
On the other hand, dendrimers are appeared as one of the most successful tools for the 
management of neurodegeneration at the nanoscale level. Dendrimers have greater capability 
for crossing BBB and targeted drug delivery with low toxicity [66], thus dendrimers emerge 
out as interesting device in treatment of NDs. It has been observed that PAMAM and 
phosphorus dendrimers indicated their anti-amyloidogenic activity [67,68]. Cieplucha et al. 
reported potential of viologen–phosphorus dendrimer for the inhibition of AChE and BChE 
activities and showed its caliber against AD [69]. Klajnertet al. investigated effect of 27 
terminal morpholine fabricated GATG (gallic acid-triethylene glycol) dendrimer on the 
9aggregation process of Aβ peptides. The developed formulation reduced the amount of 
prefibrillar forms of Aβ and ultimately lowered the toxicity of Aβ peptides [70].
On the other side, the available literature indicated the promising therapeutic potential 
of various growth factors and neurotrophins against the  AD [71–74]. Growth factors (GFs) 
like insulin-like growth factor (IGF-1/IGF-2) [75,76], bone morphogenetic proteins (BMPs) 
[71,77,78], basic fibroblast growth factor (bFGF) [79–81] and glial-derived neurotrophic 
factor, GDNF [82], neurotrophins (nerve growth factors, NGF) [83–85]; and brain-derived 
neurotrophic factor (BDNF) [86,87] are very hopeful therapeutic molecules for the 
management of NDs. Lauzon et al. discussed various strategies involving specificity 
enhancement of growth factors (GFs) to brain and provided information regarding recent 
advancement for brain targeted delivery of GFs in term of in-vivo and in-vitro effect in 
context of AD [88]. For the treatment of AD, Yang et al. developed single-walled carbon 
nanotubes (SWCNTs), which successfully delivered acetylcholine into brain then SWCNTs  
easily entered into lysosomes and reached to targeted organelles, except mitochondria [89].
Metals like copper, zinc, iron, and aluminum promoted oxidative damage is one of the 
causes of AD. FDA approved D-Penicillamine, a copper chelator to treat AD. The D-
penicillamine decreases the amount of metal ions, which promote the beta-amyloid 
deposition in AD patients. Further, it does not affect the integrity of the BBB [90].
3.2. AD diagnosis
Nanotechnology attempt more lucrative methods  over conventional assays for the 
estimation of amyloid-beta derived diffusible ligands or tau protein (pathogenic markers) in 
human CSF employed in early in-vitro diagnosis of AD [91]. In this context, nanotechnology 
indicate tremendous advantage for effective imaging of CNS functions and status of diseases 
as well as in advance neuro surgical practices. Now a day, Magnetic Resonance Imaging 
(MRI) has appeared as the vital tool for the imaging of brain disorders. Positron Emission 
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Tomography (PET) imaging also very potent in diagnosis of the various nervous system 
disorder’s mechanisms, including the pathophysiology of AD. In this course, radio-labeled 
amyloid ligands tracked the pathophysiological process of AD [92–94].
Gadolinium, iron and manganese containing nanoparticles (NPs) are extensively 
explored for their contrast activity. Among them superparamagnetic iron oxide (SPIO) NPs 
have greater surface area, magnetic properties with low toxicity, create more interest in this 
approach. Generally, core of SPIO NPs contains a crystalline iron oxide (including magnetite, 
Fe3O4, or maghemite, γFe2O3), which make it biocompatible and encased in a coated 
monomerous polymer [95,96]. The ferumoxtran-10 (dextran coated USPIO ) involved in the 
diagnosis of ischemic damage in patients of cerebral ischemia [97]. On the other hand, 
Beckmann et al. studied amyloid precursor protein mouse AD model for cerebral amyloid 
angiopathy and found that MRI detection of microvascular lesions in the brains of the mice 
was enhanced with the systemic administration of SPIOs. In case of AD, SPIO NPs s entered 
in the monocytes and traveled into the circulation then penetrate in the brain through 
chemokines due to attraction of amyloid beta (Aβ)-stimulated glial cells [98].
The clinical MRI agents like Feridex® (Endorem) and Resovist® were used as 
important tool for diagnosis of AD. The AMAG Pharma discontinued Feridex® in 2008, 
whereas in 2001, Resovist® was approved for the European market, but in 2009 its production 
was abdicated. Thus, essentially, a clinically active device for screening of AD should be 
available in the market. Li et al reviewed various nano-approaches involved in the generation 
of MRI contrast agents for cell labeling and tracking [99]. Polyethyleneglycol (PEG)-coated 
USPIO NPs may adhere with Aβ1-42 peptides and offer a wide opportunity for simultaneous 
targeting and imaging of amyloid plaques in AD transgenic mice. Thus, intravenous injection 
of these NPs transiently opens the BBB for detection of the level of amyloid plaques [100]. 
On the other hand, ultrasensitive immunosensors involve surface plasmon resonance for the 
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detection of Aβ peptides [101]. While scanning tunneling microscopy utilize specific 
immobilized mAb fragments on the surface of gold nanoparticles (Au NPs) for recognition 
and lead to electrical detection [102]. Yang et al. synthesized and marked out Aβ-40 or Aβ-42 
antibodies coated with some specific SPIO and applied them in the  immunoassay of AD 
[102]. Neely et al developed and characterized anti-tau antibodies coated Au NPs  involved in 
two-photon Rayleigh scattering assay for the  detection of CSF tau proteins [103].
Moreover, in the clinical diagnosis Aβ-40 or Aβ-42 peptides levels involve a 
comparative estimation of these peptides in normal and AD patients. The Aβ screening 
methods involved electrochemical sensing of saccharide–protein interactions, has also been 
reported [104]. In addition, with this context, Georganopoulou et al. have established 
ultrasensitive assay [105], for the determination of approximate ADDL concentration by 
utilizing Au NP bio-barcode. for the detection of tau protein, While Neely et al. [103] utilized 
photons coupled antibody coated Au NP. Recently, nano-HPLC-MS technologies also have 
been used as possible additional pathogenic marker of AD and are involved in phospholipid 
profiling of CSF, providing an opportunity to follow lipid changes [106]. On the other hand, 
streptavidin conjugated quantum dots (QDs) indicated a high sensitivity for the recognition of 
AAP for the in-vitro estimation in comparison with conventional fluoro immunoassay [107].
While in-vivo nanotechnological approaches involve the estimation of Aβ deposits in 
the brain, the deposition of β amyloid protein in AD transgenic mice was detected from μ 
MRI technique which involved Aβ-coupled iron oxide NP either superparamagnetic or mono 
crystalline form [108]. Roney et al. synthesized  polymeric n-butyl-2-cyanoacrylate NP 
enclosed with  the radio-labeled drug 125I-CQ which has affinity towards  amyloid proteins 
[109]. The obtained results indicated the BBB crossing ability of NP with rapid transportation 
and retention in the AD transgenic mice brain in comparison of controls. 
4. Nanotechnology for Parkinson's disease
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PD lead a progressive loss of neurons of  specific areas of brain approximately 1–2% 
of the population of age≤65years  is affected from PD disorder in the world [110]. PD 
involve the loss of dopaminergic neurons in the substantia nigra and pars compacta and 
results of difficulties in the movement control. The appearance of Lewy’s bodies in the brain 
of PD patients is the primary sign of this disorder. The Lewy’s bodies contain 50 to 700 nm 
long filaments of the α-synuclein proteins as cytoplasmic inclusions. Various cellular 
mechanisms such as ER stress, proteasomal and mitochondrial dysfunction are behind of 
neuronal death in PD [111].
4.1. PD therapy
At present, very limited supportive care, management and cure is available for PD. 
All these situations slow down the treatment and therapy of PD and alleviate the progression 
of disease. The available pharmacological treatment and therapy mainly pay its attention on 
restoration of dopaminergic neurotransmission [112]. 
Nanotechnological approaches lead a safe and effective strategic resolution over the 
available conventional approaches for the best remedy of PD. Tiwari et al. synthesized 
nicotine-encapsulated poly(lactic-co-glycolic)acid (PLGA) nanoparticles. At nanosize the 
bioavailability of nicotine enhanced with consequent decrease in the oxidative stress and 
apoptosis with an improved neuroprotective efficacy [113]. Recently Gerardo Leyva-Go´mez 
et al. presented an overview on technical aspects for drug delivery to the brain from the NPs. 
The study involve analysis of surface phenomena which are involved in functional 
development and synthesis of NPs for the treatment of PD [114]. Trapani et al. prepared 
specific chitosan NPs with an external DA coating. In-vivo experiments on rats indicated that 
on intraperitoneal administration, DA loaded chitosan NP have less cytotoxicity with greater 
penetration to the striatum more than DA alone [115]. Huang et al. found a significant 
improvement in locomotor activity as well as minimization of dopaminergic neuronal loss, 
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with the  increase in  DA levels in PD rat brain through the administration of human 
neurotrophic gene encapsulated in lactoferrin–modified NP [116]. In a study it has been 
observed that Odorranalectin (OL) NPs are act as potential carriers for the delivery of special 
macromolecular drugs from olfactory  route   to  brain for the treatment of PD [117]. Hu et al. 
developed lactoferrin (Lf) conjugated polyethylene glycolpolylactide-polyglycolide (PEG-
PLGA) nanoparticles (Lf-NPs) as a novel biodegradable brain drug delivery system, indicate 
auspicious drug delivery  with  less toxicity [118]. On the other side, various cationic 
dendrimers mark their candidature among the new pharmacological strategies against 
neurodegenerative disorders with the prevention of proteins fibrillation specially α-synuclein 
fibrillation in the NDs [119–121]. Many times, dendrimers can also alter functions of 
different proteins i.e. viologen-phosphorus dendrimers modified the activities of AChE and 
BChE [122]. Recently, it has been investigated that carbosilane dendrimers prevented the α-
synuclein fibrillation for the rotenone-induced damage of hippocampal cells (mHippoE-18) in 
the rat brain. An another study indicated a broad  contribution of dendrimers in the increased 
vitality, potentiation of mitochondrial membrane activity and decreased reactive oxygen 
species level in the cells of specific parts of the brain [123].
It has been found that exosomes from blood exhibit natural brain targeting ability by 
transferrin-transferrin receptor interaction. In this regard recently, Qu et al. developed 
dopamine loaded biocompatible, spherical blood exosomes of 40 and 200 nm size range for 
delivering drugs across the BBB. In vivo studies demonstrated that the blood exosomes 
successfully delivered dopamine to brain as witnessed by >15-fold increased dopamine brain 
distribution [Figure 5]. Dopamine-loaded exosomes showed lower systemic toxicity as 
compared to free dopamine and improved therapeutic efficacy in a PD mouse model [124].
4.2. PD diagnosis
14
The clinical sign of PD include loss of more than 50% of the dopaminergic neurons 
and 75–80% of striatal dopamine in the brain [125–127]. Thus, PD must be detected in early 
stages for proper treatment. At this stage, the progression of PD can be easily suspended from 
the neuroprotective medicines, so the availability of a novel biomarkers for early detection of 
PD can help in its diagnosis and treatment [128,129]. Recently, Qiang et al. described 
clinical, neuroimaging, biochemical, genetic and proteomic biomarkers, which are involved 
in PD diagnosis and treatment. Single photon emission computerized tomography (SPECT), 
used for estimation of dopaminergic pathways in the brain may be useful to diagnose PD 
[130]. In a recent study, Akhtar and Stern, described early symptomatology of Parkinson’s at-
risk syndrome with the broad study of disease biomarkers and putative disease-modifying 
therapeutics used for PD. They compared clinical diagnosis, radiological screening and 
molecular examinations involved in the early detection of PD [131].
Now a days nanotechnological approaches possess their effectiveness in diagnosis and 
imaging of PD. In this sequence, An et al. tapped high sensitivity photo electrochemical 
immunosensor, Au-doped TiO2 nanotube (NT) arrays to trace  α-synuclein proteins in CNS 
[132].  Previously, Baron et al. developed Au NP with plasmon absorbance involved in an in-
vitro quantitative estimation  for neurotransmitters involved in PD pathology [133].
5. Nanotechnology for Prion Disease (PrD)
PrD lead to stockpiling of misfolded Prion Protein (PrP) isoforms, PrD included a 
bunch of NDs. First identified prion disease in human was Creutzfeldt-Jakob disease. It is 
found periodically and about one case per million individuals per year is observed. In the 
sane individuals, cellular isoform (PrPC) of prion protein exists two large alpha-helical 
structures. While in the pathogenic protease-resistant isoform (PrPSc), predominant β-sheet is 
found that may produce toxic amyloid aggregates. When a pathogenic isoform has been 
originated, PrPC modified into PrPSc via protein-protein interaction [134].
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5.1. Prion disease therapy
Many in-vitro studies showed that different types of polyamine dendrimers are 
retracting pathogenic prion isoform (PrPSc) from lysosomal degradation and eradicate them 
from infected cells. The different polyamines have positive charges over them and their 
action depend on this positive charge. Lim et al. synthesized less toxic positively charged 
polyamines with greater potential [135]. Ai Tran et al. synthesized polyelectrolyte multilayer-
coated Au NP containing sulfonates and primary amines as functional groups on the surface 
with a great therapeutic relevancy and inhibited to PrPSc aggregation in neuroblastoma cells 
at very low dose [136]. Sousa et al. [137] indicated that Au NP coated with the similar groups 
have crossing ability across the murine BBB and enter the specify neuronal structures in 
which PrP agglutination occurs. On the other side, McCarthy et al on the bases of 
dendrimer/prion interactions, formulated a new working model which indicated that 
dendrimers destabilize the prion protein and rendering it susceptibility to proteolysis thus 
eliminate PrP(Sc) [138]. In another study, it has been found that dendrimers inhibited the 
intracellular conversion of PrPC to PrPSc while anti-prion activity is independent from their 
cationic surface charges. This work indicate inhibitory action of mPPI G5 dendrimers against 
the conversion of PrPC to PrPSc and also determine the effect of other drugs which are 
enhancing this action of  mPPI G5 dendrimer [139].
5.2. Prion disease diagnosis
Xiao et al. developed a novel diagnostic approach, involving two different type of 
aptamers which were able to recognize various epitopes of PrPSc and segregate PrPSc from 
PrPc in serum as well as in brain homogenate [140]. In this approach, the aptamers were 
attached to the surface of QDs and magnetic micro particles, in presence of PrPSc. These 
produced a highly fluorescent sand which like structure in aqueous medium and it can be 
easily isolated under the influence of external magnetic field. Xie et al. demonstrated in-vitro 
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site-specific labeling of PrP expressed on cell surfaces from PEG-interspersed nitrile triacetic 
acid-functionalized QDs [141].
6. Nanotechnology for amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis (ALS) lead to fatal neurodegeneration and affect 
approximately 1-2/10,0000 person per year. The signet of this disorder includes paralysis of 
voluntary muscles from the selective death of motor neurons in the brain and spinal cord. The 
mutations in SOD1 gene which encode superoxide dismutase enzyme is the main cause of 
ALS in approx. 20% of familial ALS cases. The mutated SOD1 gene leads to formation of 
toxic free radicals and intracellular aggregates that restrict chaperone or proteasome activity, 
with consequent mis-folding and inadequate expulsion of manifold proteins [142].
For the specific treatment of ALS, Bondì et al. synthesized riluzole solid lipid NP 
with high drug loading capacity and a greater efficacy than free riluzole. The higher drug 
loading capability with greater carrying capacity of riluzole solid lipid NP into the brain with 
lower indiscriminate bio distribution in rats open an another route for the use of NP for ALS 
therapy [143].
Recently, a rat model of ALS detection involved administration of T cells labeled 
USPIO NP in the MRI technology. The study revealed an infiltration of CD4+ lymphocyte in 
the midbrain/interbrain, while CD8+ cells were more confined to the brainstem region [144]. 
Machtoub et al. for the detection of the pathological regions in ALS rat brain, injected USPIO 
NP conjugated with anti-CD4 antibodies from intravenous route [145].
7. Nanotechnology for neuroprotection and neuronal tissue regeneration
7.1. Neuroprotection
Most of the time, a higher level of reactive oxygen species is involved in CNS 
injuries. It has been observed that multiple radicals able to incorporate per-molecule similar 
as radical sponges, but  a delocalized π double bond system eradicate superoxide radicals 
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over the dis-mutation catalytic mechanism [146]. A study indicated that a trismalonic acid 
derivative of the fullerene C60 molecule (C3) is able  to raise the life span of mice about 
300%  while lacking mitochondrial manganese superoxide dismutase (MnSOD) [147]. On the 
other hand, cerium oxide NP (nanoceria) are established as neuroprotective agents lead to 
higher antioxidant properties and guard the cells from death due to oxidative stress shown in 
In-vitro experiments on isolated rat spinal cord neurons [148].
7.2. Neuronal tissue regeneration
The strategies for repair of damaged neuronal tissues involve the extracellular 
scaffolds which attached neuronal tissues and facilitate axonal growth. Neurotrophins (NT) 
and nanofibres (NF) have structural similarities with neuronal tissues, widely used as 
regenerative medicines. Jin et al. [149] recently synthesized a multi-walled carbon nano tube  
coated with electrospun poly (l-lactic acid-co-caprolactone) NF, indicated its potential for the 
prohibition of outgrowth of  neurite in in-vitro experiments. On the other side, NT/NF both 
are utilized as scaffold and carrier for neurotrophin delivery, thus are involved in promotion, 
proliferation and differentiation of neurons. In-vivo experiments indicated that the 
incorporating potential of NF for nerve growth factor lead to effective regeneration and 
promotion of sciatic nerve [150]. One another approach leads to synthesis of electrically 
conducting NT/NF scaffolds for the enhancement of the regenerative processes with the 
future aspect for potentiating brain circuit activity. Electrically conducting nano-scaffolds 
broadly used in electrical stimulation of nerve stem cells due to their low obstruction and 
high charge transfer abilities [151]. Lee et al. in a combined approach, synthesized PLGA NF 
with electrically conducting polypyrrole covering which in in-vitro experiments act with 
nerve growth factor and lead neurite formation and outgrowth [152].
8. Neurotoxicity of NM
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In spite of greater potential of NM in the field of biomedical, there is some possible 
toxic effect of NM also observed on CNS [49,137,153]. The available data indicated that 
various factors including shape, surface area, surface charge, size, chemical composition are 
responsible for toxicity of NM. At the latest, on the bases of surface chemistry (bare, \NH2 
or\COOH functionalized) SPIONs has been investigated in-vitro neurotoxicity of on human 
neuroblastoma cell line at both cellular and molecular levels. It has been observed from MTT 
assay that the bare SPIONs have greater toxicity than those coated SPIONs, due to their 
increased tendency for absorption capability to vitamins, amino acids, and ions, leading to 
changes in pH and composition in cells and cell medium. DNA micro array experiments 
manifested that SPIONs-COOH provoke the up regulation of oxidative stress-inducible genes 
[154].Various factors like size, shape (spheres, rods, and urchins)and surface coating (PEG or 
acetyl trimethyl ammonium bromide) of gold NP has been investigated via in-vitro and in-
vivo experiments in term of their neurotoxicity.
Positively charged Au NPs exhibited toxicity on microglia and neurons during in-
vitro experiments, independently of the shape. The intranasal administration of Au NPs 
during in-vivo experiments induced TLR-2 promoter activity and transient microglia 
activation in transgenic mice. The induction and the affinity depended on shape and surface 
of NP. Moreover, it has been observed that spheres, in particular 50 nm sized Au NPs 
indicated significantly great extent of cell interactions than rods [155].
For the investigation of neurotoxicity of commercially available NTs, PC12 cells are 
is commonly used in-vitro model for neuro toxicity studies. During an experiment, it has been 
observed that NTs decreased PC12 cell viability and mitochondrial membrane potential, 
dependent on time and dose while an increase in ROS production, the cell cycle arrest in the 
G2/M phase and the apoptotic rate depend only on the dose of NTs [156].
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Zhang et al. found that the exposure of  TiO2 NP lead morphological changes of 
cortex neurons and disturb the levels of monoamine neurotransmitter in the sub-brain areas 
[8,157]. At the beginning some NP, indicated promising features in therapy and diagnosis but 
simultaneously their toxicity in the in-vivo experiments limited their clinical use. In the case 
of QD and NTs, repeated in-vivo toxicity limited their future use at the level of in vitro 
diagnosis. Thus, the benefit-risk balance should be carefully evaluated for nano technological 
approaches promised for brain drug delivery and diagnostics.
8. Recent advancement in therapeutic strategies of neurodegenerative disorders
8.1. Cannabinoid therapeutics 
The classic hallmarks of the aged brain and neurodegenerative conditions involve 
abnormal protein accumulation, impaired lysosomal system, oxidative stress, excitotoxicity, 
and neuroinflammation [158]. The endocannabinoid system (ECS) has been emerged as a 
viable target for symptom alleviation or disease progression based on pharmacological 
modulation of endocannabinoid signaling, which involves both cannabinoid receptor-
dependent effects and cannabinoid receptor independent effects [159]. The cannabinoid 
receptor-dependent effects are (i) activation of cannabinoid type-1 (CB1) receptors to 
normalize glutamate homeostasis or to activate autophagy; (ii) activation of cannabinoid 
type-2 (CB2) receptors and peroxisome proliferator-activated receptor γ (PPARγ); (iii) 
modulation of G-protein receptor 55 (GPR55) to reduce local inflammatory events [160].
8.2. Human fetal neural stem cell therapy
Clinical trials using primary brain fetal tissue demonstrated the suitability of neural 
stem cell (NSC) therapy for neurodegenerative diseases. Based on supportive, preclinical 
proof-of-principle data, up to 21 somatic stem cell-based pilot trials have been developed for 
the treatment of ALS [161].  Immune-deficient models represent one of the elective 
experimental paradigms for the analysis of putative tumorigenicity of hNSC in vivo. Three of 
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those studies have used hNSC lines: NCT01640067, NCT01348451 and NCT01730716. 
Interestingly, all the studies confirmed no acceleration in the course of the disease; on the 
contrary some of the patients showed a transient improvement of motor functions and ALS-
FRS scale [162–164]. Although the data are encouraging, however this type of conclusions 
should be addressed more properly in larger phase II/III trial.
8.3. 3D human brain cell models for neurodegenerative diseases
Reason behind a high degree of failure in many recent clinical trials for
disease-modifying therapeutics is the difficulty of translating findings from animal-based cell 
models to human patients. The majority of non-animal neurodegenerative disease research 
has been conducted in 2 dimensional (2D) models of rodent neonatal neurons and glia. The 
human stem cell technologies combined with microfluidic technologies have opened the door 
to development of patient-derived 3D brain cell models with the advantage in providing a 
micro-physiological system more closely reflecting the in vivo brain environment,
and promote the interaction between different patient-derived brain cell-types. The new 
patient derived 3D brain cell systems will likely improve translational
outcomes for disease therapeutics [165].
9. Perspectives and conclusion
Nowadays, scientists are investigating molecular, cellular and circuit functions of the 
CNS for the identification of causes and the pathways involved in neurodegeneration. The 
nanotechnological approaches are very progressive from the last few years in the direction of 
diagnosis and treatment of neurodegenerative disorders. However, more endeavors will be 
required in this arena for the conversion of preclinical experiments to substantial clinical 
exercises.
This is an arduous challenge for researchers, to develop feasible, compatible and 
acceptable theranostic NM for neurodegenerative disorders. Currently used magnetic ones 
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indicated a successful candidature as theranostic due to their magnetic properties that may be 
utilized for MRI, tissue engineering and cell tracking, targeted drug and gene delivery 
systems. Recently, nanotechnology continuously working for development of novel tools 
which will emerge new insights in treatment and diagnosis of NDs.
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Figure captions:
Figure 1 (A) Graphical representation of theranostics system; (B) Current application of 
theranostics nanotechnology in pharmaceutical field.
Figure 2 (A) An insight of blood brain barrier (BBB); (B) Schematic representation of 
different transport pathways across the BBB [166].
Figure 3 Desired features of nanomaterials
Figure 4 Pictorial representation of treatment of neuro-diseases from nanomedicine
Table captions:
Table 1: Overview of various neuro-therapies and interventions for CNS disorders.
Table 2: Advantages of different NPs for the treatment of Alzheimer’s disorder.
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Table 1: Overview of various neuro-therapies and interventions for CNS disorders.
Disorder Type of 
Nanostructure
 Therapeutic 
Agents 
Mechanism of Action Reference
Polymeric 
nanoparticles
Poly(alkyl 
cyanoacrylate) 
and 
poly(lactic 
acid) NPs
 These engineered long-circulating NPs 
may have the ability to capture the toxic 
forms of the Aβ(1-42) peptide from the 
systemic circulation and potentially 
improve Alzheimer's disease condition 
through the proposed "sink effect".
[167]
Poly(propylene 
imine) (PPI) 
glycodendrimers
Electroneutral 
maltose shell
 Modify the total burden of β-amyloid [168]
Dendrimer  Lysine base Protect cells against Aβ-induced 
cytotoxicity and K+ channel modulation
[169]
Chitosan 
nanoparticles
Tacrine Release of drug from nanoparticles was 
diffusion-controlled
[170]
Alzheimer’s 
disease
Polymeric 
nanoparticle 
Curcumin Decreased levels of H2O2, increased 
glutathione (GSH) concentrations and 
create redox intracellular environment
[171]
Nanoparticles Curcumin Curcumin nanoparticles increase 
neuronal differentiation by activating 
the Wnt/β-catenin pathway, involved in 
regulation of neurogenesis
[172]
 Lactoferrin (Lf) 
conjugated 
polyethylene 
glycol-polylactide-
polyglycolide 
(PEG-PLGA) 
nanoparticle (Lf-
NP)
Urocortin Lf-NP effectively attenuated the 
striatum lesion 
[118]
Poly(ethylene 
glycol)–
poly(lactic-co-
glycolic acid) 
(PEG–PLGA) 
nanoparticles 
Urocortin 
peptide 
(UCN)
OL modification increased the brain 
delivery of nanoparticles and enhanced 
the therapeutic effects of UCN-loaded 
nanoparticles on Parkinson's disease
[117]
 Poly-L-lysine 
(DGL) 
dendrigraft/NPs
Gene 
encoding 
human glial 
cell line-
derived 
neurotrophic 
factor 
(hGDNF), 
DPA/hGDNF
Improved locomotor activity and 
apparent recovery of dopaminergic 
neurons
[173]
Dendrimers  L-DOPA DOPA dendrimers showed an increased 
aqueous solubility and enhanced 
photostability
[174]
Dendrimers Viologen-
phosphorus
Viologen-phosphorus dendrimers inhibit 
ASN fibril formation
[121]
Parkinson's 
disease
PAMAM G4 
dendrimer
PAMAM G4 
dendrimer
Increase in tyrosine residue 
fluorescence, and inhibited fibrillation 
of ASN
[119]
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Table 2: Advantages of different NPs for the treatment of Alzheimer’s Disorder
Type of 
nanoparticle
Therapeuti
c Agents
Preparation 
method
Advantages/ 
applications
Route of
administrati
on
Referenc
e
Polystyrene
nanoparticles
Metal
chelators
a) Copper
chelator
-D 
Penicillami
ne
Conjugation of 
drug and 
nanoparticles
Deliver D-
penicillamine to
the brain for the 
prevention
of Aβ (1–42) 
accumulation
[175]
Polystyrene
nanoparticles
b) Iron
chelator
— MAEHP
Polystyrene 
nanoparticles 
activated by
N-cyclohexyl-N_-
(2-morpholino 
ethyl)
carbodiimide 
methyl-p-
toluensulfonate
and then reacted 
with the iron
chelator, 2-methyl-
N-(2_-aminoethyl)-
3-hydroxyl-4-
pyridinone
Nanoparticle–
chelator conjugates
have the potential 
to inhibit Aβ
fibril formation and 
to cross the BBB 
and protect human 
brain cells from 
Aβ-related toxicity
[176]
Polymeric n-
butyl-
2-
cyanoacrylate
Quinoline
derivatives
— 
Clioquinol
Polymerization 
technique
Drug loaded 
nanoparticles 
exhibited
specificity for Aβ 
plaques both in 
vitro and in vivo; 
capable of aiding in 
the early diagnosis 
of AD
i.v. injection [177]
Chitosan 
nanoparticles
Hormones
— Estradiol
Prepared by ionic 
gelation of chitosan
with 
tripolyphosphate 
anions (TPP)
Chitosan 
nanoparticles 
significantly
increase the 
transport of 
estradiol into the
central nervous 
system
Intranasal
administratio
n
[178]
Poly (ethylene 
glycol)-poly
(lactic acid) 
nanoparticles
modified with 
wheat germ
Proteins 
and
peptides
—VIP
Produced by 
emulsion/solvent
evaporation 
technique
Improvement in 
brain delivery of 
estradiol
using wheat germ 
agglutinin 
nanoparticles
Intranasal
administratio
n
[179]
38
agglutinin
a) 
Polysorbate-
80
coated poly 
(nbutylcyanoa
crylate)
NP
ChEIs
—Tacrine
Enhanced 
concentration of 
the drug in the 
brain
i.v. injection [180]
Chitosan 
nanoparticles
ChEIs
—Tacrine
Spontaneous 
emulsification
method
A new drug 
delivery system for 
increasing
bioavailability of 
the drug in the 
brain
i.v. injection [170]
Core–shell 
nanoparticles
composed of a 
polystyrene
core and a 
degradable 
PBCA
[poly (butyl-
2-cyano 
acrylate)]
shell
Amyloid β
targeted
drugs
—
Thioflavin 
T
and S
Emulsion 
polymerization
method
Tools to trace and 
clear Aβ in the 
brain
Intracerebro 
ventricular
injections
[181]
Poly (n-butyl 
cyanoacrylate
)
Rivastigmi
ne
Emulsion 
polymerization
method
3.82 folds increase 
in brain 
concentration
of the drug
I.v. injection [182]
Viologen–
phosphorus 
dendrimers
Conjugation 
Method
Non-toxic
viologen–
phosphorus 
dendrimers 
inhibited the 
activities of both 
cholinesterases, 
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Figure 1 (A) Graphical representation of theranostics system; (B) Current application of 
theranostics nanotechnology in pharmaceutical field.
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Figure 2 (A) An insight of blood brain barrier (BBB); (B) Schematic representation of 
different transport pathways across the BBB [166].
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Figure 3 Desired features of nanomaterials
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Figure 4 Pictorial representation of treatment of neuro-diseases from nanomedicine
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2Abstract:
Conventional drug delivery systems are inadequate in providing essential cyto-architecture 
restoration and connection patterns because of restrictions posed by the restrictive blood-
brain barrier. Nanotechnological approaches involve various nano-sized carrier systems and 
other devices, which stimulate the action of therapeutic agents on molecular level and 
revolutionized the treatment and diagnosis of neurodegenerative disorders with minimal side 
effects. Over the conventional approaches, nanotechnological approaches have various 
promising strategies to cross blood brain barrier and increase the bioavailability of 
therapeutics in brain. This review article emphasizes the current and future utility of nano 
drug delivery systems for the treatment of various neurodegenerative disorders.
Keywords: Neurodegenerative disorder; Parkinson disease; Nanotechnology; Alzheimer.
31. Introduction
Neurodegenerative disorders (NDs) inscribe the progressive damage of neurons, 
usually concerned with death of neuronal cells. Various types of NDs like Alzheimer's (AD), 
Parkinson's (PD), Prion (PrD) disease and Amyotrophic Lateral Sclerosis (ALS) are 
associated with the neuronal damage in the different areas of brain and spinal cord. At present 
the available diagnosis and treatment strategies for NDs are inadequate to inhibit the 
progression of the brain injury or degeneration. The blood-brain barrier (BBB) appeared as  
one of the most arduous hurdles for the transport of therapeutic or imaging contrast agent into 
the nervous system [1–4]. While the available potentials for imaging and therapy of brain 
disorders mostly depend on the vascular and penetration ability across the BBB [5–7], for the 
rectification of these problems, a novel, safe and more sensitive imaging modality with 
improved therapeutic potential is immediately required. The nanoneuro-medicine offer 
innovative and promising approaches to address the NDs as well as other nervous system 
diseases for which limited options are available [8].
Theranostics, the nanotechnology-based devices, have ability to deliver therapeutic, 
imaging and diagnostic agents at a time [9]. However current practices of nanotechnology in 
pharmaceutical field have been represented in Figure 1A & 1B. Nanomedicine and other 
related technologies improve transportation of biological active/imaging/contrast agents from 
the BBB; increase the drug-carrier bond with clearance of pathogens from nervous system 
[10]. At present various types of nanomaterials are available with different physicochemical 
and therapeutic properties. The nanomedicines have tremendous positive features like greater 
chemical or biological substantiality, incorporating capability for hydrophilic as well as 
hydrophobic molecules, can be used in the treatment or diagnosis of various NDs (Table 1). 
In addition, the nanomedicines can administer from several routes like olfactory, oral and 
4systemic etc. This review highlights variety of features of nano technological approaches 
involved in the treatment and prognosis of various NDs.
1.1 Latest developments in nanotechnology, nanomaterials and nanoarchitectonics
Recently, in the field of nanomedicine Li et al. developed layer-by-layer self-
assembled stacked Testudo-like MoS2-NS superstructures carrying doxorubicin (Dox) and 
DNA oligonucleotides, which was considered as a base platform, achieving high efficacy and 
autonomous ATP responsive drug delivery [11,12].
Single walled carbon nanohorns (CNHs) are graphene-based tubules having 25 nm 
diameter and 4050 nm length. In medical field, their potential uses are in drug delivery, 
diagnosis, and clinical tests. Nakamura et al. developed micelles based drug delivery system 
by dispersing CNH in phospholipid poly(ethylene glycol) (PLPEG) and revealed the effect of 
PLPEG quantity on the cytotoxicity of PLPEG-CNH in RAW264.7 mouse macrophages. The 
optimum PLPEG:CNH weight ratio was found to be 0.5:1 and 1:1. At the higher or lower 
ratios, the PLPEG-CNH toxicity and the macrophage uptake quantity increased and large 
agglomerates appeared [13]. 
Carbon nanotubes (CNTs), one of the emerging members of carbon family are 
potentially used in sensing, bone scaffolds, drug and gene delivery, composite materials, and 
water purification. The credit for successful applications of CNTs goes to desired 
conductivity, specificity, selectivity, high aspect ratio, high porosity and loading, ease in 
surface modification, and non-toxicity [14]. 
Radioisotopes are frequently used for various medical applications. Nowadays, a 
considerable quantity of 99mTc is generated in hospital using 99Mo/99mTc generators. In this 
regard, Saptiama et al. prepared mesoporous alumina (MA) materials as potential adsorbents 
for molybdenum (Mo) using a soft-templated method. The change in calcination temperature 
from 600 to 900 °C improved the crystallinity but decreased the surface area and the pore 
5volume of the MA materials. These results can guide the design of effective Mo adsorbents 
based on mesoporous materials toward 99Mo/99mTc generator preparation[15].
Nanoarchitectonics involves architecting of materials in the nanoscale. There are two 
types of bio-related nanoarchitectonics i.e. DNA nanoarchitectonics and cell macromolecular 
nanoarchitectonics. The former involves functionalization of single DNAs by chemical 
method to achieve stronger DNA binding, DNA aptamers and DNAzymes. Programmable 
assemblies of DNAs find their applications for selective labeling of biomaterials in cells and 
in animals, delivery of drugs to target sites and sensing in vivo. The later involves the 
construction of highly organized synthetic/natural macromolecular modified hybrid 
biointerfaces [16,17].
2. Nanotechnology across the BBB
The BBB is a physical and biological occlusion present in amid of central nervous 
system (CNS) and systemic blood circulation, protects brain from unwanted substances and 
other intruders [18]. The BBB contains endothelial cells, smooth muscle cells, pericytes, 
microglial cells and astrocytes with a tight junction amongst them and restrict the 
transcellular flux (Figure 2A) [19–21]. Currently, nanotechnology appears as promising 
strategy in which the nanomaterials interact with BBB at molecular level and transport across 
the BBB through existing mechanisms (Figure 2B) [20,22], without any intervention in the 
usual function of BBB and itself [23]. The nanomaterials have transcellular movement from 
blood to brain across the BBB with transcytosis movement involve receptor as well as 
adsorption mediated mechanism [24]. To achieve brain targeting across the BBB, the 
nanomaterials must have many competencies like minimum surface area, prolonged half-life 
in blood, nontoxic, biodegradable, biocompatibility, non-inflammatory and non-
immunogenic with avoidance of reticulo-endothelial system (Table 2) [25–29]. The vital 
features of nanomaterials are depicted in Figure 3.
62.1. Adsorptive-mediated transcytosis
Adsorptive-mediated transcytosis lead to electrostatic interaction of a ligand with the 
luminal surface charges of endothelial cells. The fabrication cell penetration peptides (e.g. 
TAT-derived peptides) and cationic proteins (e.g. albumin) on the surface of nanomaterials 
facilitate the passage across the BBB [24,30]. Thus, the addition of different domains like 
glycosylation [31], methylation [32] PEGylation [33–38], lipophilic domains [39,40], virus 
glycoprotein [41,42] or coating with polysorbates [24] on the surface of different types of 
nano devices lead to an enhanced penetration potential across the BBB. The diffusivity of 
nano devices across the BBB, several times depends on the material used in the coating, 
charge of the surface and the matrix of these particulate systems. An albumin coating, reduce 
the interaction between extracellular space proteins and decrease the size effect on the 
distribution of nanospheres [40,43]. Thus, these nanocarriers have greater optimization in 
convection enhanced delivery (CED) [42,44].
2.2. Receptor-mediated transcytosis
Receptor mediated transcytosis is more intensively explored physiological procedure. 
This involves the transportation of various nanomaterials across the BBB based on affinity 
towards the receptors of BBB cells. Receptor mediated transcytosis is achieved by addition of 
some specific proteins such as insulin [45], transferrin [46], apolipoprotein [47,48], macro-
globins and other small peptides that are able to act as ligands for the receptors located on 
cells of BBB.  
Certain monoclonal antibodies (mAbs) undergo receptor mediated transcytosis and 
are directed towards the receptors on BBB. Like the binding of OX26,8D3 & R17217 mAbs 
with transferrin, receptors recognize different epitopes and avert the competition with innate 
transferrin in blood [49]. On the other hand, some mAbs involved in construction of brain 
targeted drug delivery devices are directed against insulin receptors [50].
73. Nanotechnology for AD
Literature suggests that AD affects more than 24 million people worldwide. 
Alzheimer’s disease lead to onward loss or deterioration of neurons of cortical and 
hippocampal leads to memory and cognitive dysfunction [51]. Another neuropathological 
hallmark of AD is appearance of neurofibrillary tangles containing hyper-phosphorylated tau 
protein on intraneuronal paired helical filaments and extracellular plaques of β amyloid 
peptide (Aβ). Aβ are small fragments of amyloid precursor proteins (APP) containing 39-43 
amino acids. Thus, the aggregation of small segments of Aβ (ADDLs, amyloid-β-derived 
diffusible ligands) are mainly responsible for memory deficits and synaptic damage in AD 
[52,53].
3.1. AD therapy
At present, the available therapies of AD are based on cholinergic progress, 
particularly on the cholinesterase (AChE and BChE) activities prohibition [54]. Although 
cholinergic inhibitors have greatest benefit for cognitive dysfunction, these are unable to 
compensate the continuous loss of hippocampal and cortical neurons. Currently the treatment 
of AD depends on acetylcholinesterase  (AChE) inhibitors (Rivastigmine, Dopenezil, 
Galantamine) or NMDAR inhibitor (Memantine) indicate only momentary effect but unable 
to stop  disease progress and mainly administered orally or transdermally [55–57].
In year 2000, Rivastigmine, a non-competitive and reversible AChE inhibitor was 
approved by the FDA for the treatment of AD [58]. Now a day, nanotechnological strategies 
are employed for enhancing the potency of AD therapies (Figure 4). The nanotechnological 
devices target to Aβ aggregation and fragmentation of APP, not only in CNS even in blood 
with the approach of reducing its level in brain[59].The reduction of Aβ aggregation and 
fragmentation of APP in the brain is known as ‘sink effect’. Gobbi et al. developed 
nanoliposomes (NLs) utilizing phosphatidic acid or cardiolipin [60]. In an another study it 
8has been observed that these NLs have greater affinity towards Aβ and diminished the 
toxicity of these peptides in ex-vivo condition [61]. Canovi et al. developed NL formulation 
with anti-Aβ mAb, indicating higher affinity for Aβ in ex-vivo as well as in vivo studies [62]. 
In addition to these, Mourtas et al. developed another formulation of NL with curcumin 
derivative, which displayed high affinity towards Aβ and inhibited Aβ aggregation in an in 
vitro model [63,64].
Amyloid fibrillar deposition of misfolded proteins can be exploited for both therapy 
and diagnosis of AD. Recently, Orteca et al. developed structurally modified curcumin 
(phtalimmide derivative, K2F21) scaffold for improving its bioavailability, pharmacokinetic 
stability in physiological conditions, and in vitro ability to interfere with β-amyloid fibrils 
and aggregates at different incubation time. Computational simulations established the 
modification in conformational dynamics and interaction with the amyloidogenic region of 
the protofibril facilitating disaggregation on ligand binding. In vitro results reflected safety 
and protection against glutamate toxicity in hippocampal HT-22 mouse cells at 1 μM 
concentration. Authors claimed that the developed derivative of curcumin appeared as a 
promising candidate for both diagnosis and therapy of AD [65].
On the other hand, dendrimers are appeared as one of the most successful tools for the 
management of neurodegeneration at the nanoscale level. Dendrimers have greater capability 
for crossing BBB and targeted drug delivery with low toxicity [66], thus dendrimers emerge 
out as interesting device in treatment of NDs. It has been observed that PAMAM and 
phosphorus dendrimers indicated their anti-amyloidogenic activity [67,68]. Cieplucha et al. 
reported potential of viologen–phosphorus dendrimer for the inhibition of AChE and BChE 
activities and showed its caliber against AD [69]. Klajnertet al. investigated effect of 27 
terminal morpholine fabricated GATG (gallic acid-triethylene glycol) dendrimer on the 
9aggregation process of Aβ peptides. The developed formulation reduced the amount of 
prefibrillar forms of Aβ and ultimately lowered the toxicity of Aβ peptides [70].
On the other side, the available literature indicated the promising therapeutic potential 
of various growth factors and neurotrophins against the  AD [71–74]. Growth factors (GFs) 
like insulin-like growth factor (IGF-1/IGF-2) [75,76], bone morphogenetic proteins (BMPs) 
[71,77,78], basic fibroblast growth factor (bFGF) [79–81] and glial-derived neurotrophic 
factor, GDNF [82], neurotrophins (nerve growth factors, NGF) [83–85]; and brain-derived 
neurotrophic factor (BDNF) [86,87] are very hopeful therapeutic molecules for the 
management of NDs. Lauzon et al. discussed various strategies involving specificity 
enhancement of growth factors (GFs) to brain and provided information regarding recent 
advancement for brain targeted delivery of GFs in term of in-vivo and in-vitro effect in 
context of AD [88]. For the treatment of AD, Yang et al. developed single-walled carbon 
nanotubes (SWCNTs), which successfully delivered acetylcholine into brain then SWCNTs  
easily entered into lysosomes and reached to targeted organelles, except mitochondria [89].
Metals like copper, zinc, iron, and aluminum promoted oxidative damage is one of the 
causes of AD. FDA approved D-Penicillamine, a copper chelator to treat AD. The D-
penicillamine decreases the amount of metal ions, which promote the beta-amyloid 
deposition in AD patients. Further, it does not affect the integrity of the BBB [90].
3.2. AD diagnosis
Nanotechnology attempt more lucrative methods  over conventional assays for the 
estimation of amyloid-beta derived diffusible ligands or tau protein (pathogenic markers) in 
human CSF employed in early in-vitro diagnosis of AD [91]. In this context, nanotechnology 
indicate tremendous advantage for effective imaging of CNS functions and status of diseases 
as well as in advance neuro surgical practices. Now a day, Magnetic Resonance Imaging 
(MRI) has appeared as the vital tool for the imaging of brain disorders. Positron Emission 
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Tomography (PET) imaging also very potent in diagnosis of the various nervous system 
disorder’s mechanisms, including the pathophysiology of AD. In this course, radio-labeled 
amyloid ligands tracked the pathophysiological process of AD [92–94].
Gadolinium, iron and manganese containing nanoparticles (NPs) are extensively 
explored for their contrast activity. Among them superparamagnetic iron oxide (SPIO) NPs 
have greater surface area, magnetic properties with low toxicity, create more interest in this 
approach. Generally, core of SPIO NPs contains a crystalline iron oxide (including magnetite, 
Fe3O4, or maghemite, γFe2O3), which make it biocompatible and encased in a coated 
monomerous polymer [95,96]. The ferumoxtran-10 (dextran coated USPIO ) involved in the 
diagnosis of ischemic damage in patients of cerebral ischemia [97]. On the other hand, 
Beckmann et al. studied amyloid precursor protein mouse AD model for cerebral amyloid 
angiopathy and found that MRI detection of microvascular lesions in the brains of the mice 
was enhanced with the systemic administration of SPIOs. In case of AD, SPIO NPs s entered 
in the monocytes and traveled into the circulation then penetrate in the brain through 
chemokines due to attraction of amyloid beta (Aβ)-stimulated glial cells [98].
The clinical MRI agents like Feridex® (Endorem) and Resovist® were used as 
important tool for diagnosis of AD. The AMAG Pharma discontinued Feridex® in 2008, 
whereas in 2001, Resovist® was approved for the European market, but in 2009 its production 
was abdicated. Thus, essentially, a clinically active device for screening of AD should be 
available in the market. Li et al reviewed various nano-approaches involved in the generation 
of MRI contrast agents for cell labeling and tracking [99]. Polyethyleneglycol (PEG)-coated 
USPIO NPs may adhere with Aβ1-42 peptides and offer a wide opportunity for simultaneous 
targeting and imaging of amyloid plaques in AD transgenic mice. Thus, intravenous injection 
of these NPs transiently opens the BBB for detection of the level of amyloid plaques [100]. 
On the other hand, ultrasensitive immunosensors involve surface plasmon resonance for the 
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detection of Aβ peptides [101]. While scanning tunneling microscopy utilize specific 
immobilized mAb fragments on the surface of gold nanoparticles (Au NPs) for recognition 
and lead to electrical detection [102]. Yang et al. synthesized and marked out Aβ-40 or Aβ-42 
antibodies coated with some specific SPIO and applied them in the  immunoassay of AD 
[102]. Neely et al developed and characterized anti-tau antibodies coated Au NPs  involved in 
two-photon Rayleigh scattering assay for the  detection of CSF tau proteins [103].
Moreover, in the clinical diagnosis Aβ-40 or Aβ-42 peptides levels involve a 
comparative estimation of these peptides in normal and AD patients. The Aβ screening 
methods involved electrochemical sensing of saccharide–protein interactions, has also been 
reported [104]. In addition, with this context, Georganopoulou et al. have established 
ultrasensitive assay [105], for the determination of approximate ADDL concentration by 
utilizing Au NP bio-barcode. for the detection of tau protein, While Neely et al. [103] utilized 
photons coupled antibody coated Au NP. Recently, nano-HPLC-MS technologies also have 
been used as possible additional pathogenic marker of AD and are involved in phospholipid 
profiling of CSF, providing an opportunity to follow lipid changes [106]. On the other hand, 
streptavidin conjugated quantum dots (QDs) indicated a high sensitivity for the recognition of 
AAP for the in-vitro estimation in comparison with conventional fluoro immunoassay [107].
While in-vivo nanotechnological approaches involve the estimation of Aβ deposits in 
the brain, the deposition of β amyloid protein in AD transgenic mice was detected from μ 
MRI technique which involved Aβ-coupled iron oxide NP either superparamagnetic or mono 
crystalline form [108]. Roney et al. synthesized  polymeric n-butyl-2-cyanoacrylate NP 
enclosed with  the radio-labeled drug 125I-CQ which has affinity towards  amyloid proteins 
[109]. The obtained results indicated the BBB crossing ability of NP with rapid transportation 
and retention in the AD transgenic mice brain in comparison of controls. 
4. Nanotechnology for Parkinson's disease
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PD lead a progressive loss of neurons of  specific areas of brain approximately 1–2% 
of the population of age≤65years  is affected from PD disorder in the world [110]. PD 
involve the loss of dopaminergic neurons in the substantia nigra and pars compacta and 
results of difficulties in the movement control. The appearance of Lewy’s bodies in the brain 
of PD patients is the primary sign of this disorder. The Lewy’s bodies contain 50 to 700 nm 
long filaments of the α-synuclein proteins as cytoplasmic inclusions. Various cellular 
mechanisms such as ER stress, proteasomal and mitochondrial dysfunction are behind of 
neuronal death in PD [111].
4.1. PD therapy
At present, very limited supportive care, management and cure is available for PD. 
All these situations slow down the treatment and therapy of PD and alleviate the progression 
of disease. The available pharmacological treatment and therapy mainly pay its attention on 
restoration of dopaminergic neurotransmission [112]. 
Nanotechnological approaches lead a safe and effective strategic resolution over the 
available conventional approaches for the best remedy of PD. Tiwari et al. synthesized 
nicotine-encapsulated poly(lactic-co-glycolic)acid (PLGA) nanoparticles. At nanosize the 
bioavailability of nicotine enhanced with consequent decrease in the oxidative stress and 
apoptosis with an improved neuroprotective efficacy [113]. Recently Gerardo Leyva-Go´mez 
et al. presented an overview on technical aspects for drug delivery to the brain from the NPs. 
The study involve analysis of surface phenomena which are involved in functional 
development and synthesis of NPs for the treatment of PD [114]. Trapani et al. prepared 
specific chitosan NPs with an external DA coating. In-vivo experiments on rats indicated that 
on intraperitoneal administration, DA loaded chitosan NP have less cytotoxicity with greater 
penetration to the striatum more than DA alone [115]. Huang et al. found a significant 
improvement in locomotor activity as well as minimization of dopaminergic neuronal loss, 
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with the  increase in  DA levels in PD rat brain through the administration of human 
neurotrophic gene encapsulated in lactoferrin–modified NP [116]. In a study it has been 
observed that Odorranalectin (OL) NPs are act as potential carriers for the delivery of special 
macromolecular drugs from olfactory  route   to  brain for the treatment of PD [117]. Hu et al. 
developed lactoferrin (Lf) conjugated polyethylene glycolpolylactide-polyglycolide (PEG-
PLGA) nanoparticles (Lf-NPs) as a novel biodegradable brain drug delivery system, indicate 
auspicious drug delivery  with  less toxicity [118]. On the other side, various cationic 
dendrimers mark their candidature among the new pharmacological strategies against 
neurodegenerative disorders with the prevention of proteins fibrillation specially α-synuclein 
fibrillation in the NDs [119–121]. Many times, dendrimers can also alter functions of 
different proteins i.e. viologen-phosphorus dendrimers modified the activities of AChE and 
BChE [122]. Recently, it has been investigated that carbosilane dendrimers prevented the α-
synuclein fibrillation for the rotenone-induced damage of hippocampal cells (mHippoE-18) in 
the rat brain. An another study indicated a broad  contribution of dendrimers in the increased 
vitality, potentiation of mitochondrial membrane activity and decreased reactive oxygen 
species level in the cells of specific parts of the brain [123].
It has been found that exosomes from blood exhibit natural brain targeting ability by 
transferrin-transferrin receptor interaction. In this regard recently, Qu et al. developed 
dopamine loaded biocompatible, spherical blood exosomes of 40 and 200 nm size range for 
delivering drugs across the BBB. In vivo studies demonstrated that the blood exosomes 
successfully delivered dopamine to brain as witnessed by >15-fold increased dopamine brain 
distribution [Figure 5]. Dopamine-loaded exosomes showed lower systemic toxicity as 
compared to free dopamine and improved therapeutic efficacy in a PD mouse model [124].
4.2. PD diagnosis
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The clinical sign of PD include loss of more than 50% of the dopaminergic neurons 
and 75–80% of striatal dopamine in the brain [125–127]. Thus, PD must be detected in early 
stages for proper treatment. At this stage, the progression of PD can be easily suspended from 
the neuroprotective medicines, so the availability of a novel biomarkers for early detection of 
PD can help in its diagnosis and treatment [128,129]. Recently, Qiang et al. described 
clinical, neuroimaging, biochemical, genetic and proteomic biomarkers, which are involved 
in PD diagnosis and treatment. Single photon emission computerized tomography (SPECT), 
used for estimation of dopaminergic pathways in the brain may be useful to diagnose PD 
[130]. In a recent study, Akhtar and Stern, described early symptomatology of Parkinson’s at-
risk syndrome with the broad study of disease biomarkers and putative disease-modifying 
therapeutics used for PD. They compared clinical diagnosis, radiological screening and 
molecular examinations involved in the early detection of PD [131].
Now a days nanotechnological approaches possess their effectiveness in diagnosis and 
imaging of PD. In this sequence, An et al. tapped high sensitivity photo electrochemical 
immunosensor, Au-doped TiO2 nanotube (NT) arrays to trace  α-synuclein proteins in CNS 
[132].  Previously, Baron et al. developed Au NP with plasmon absorbance involved in an in-
vitro quantitative estimation  for neurotransmitters involved in PD pathology [133].
5. Nanotechnology for Prion Disease (PrD)
PrD lead to stockpiling of misfolded Prion Protein (PrP) isoforms, PrD included a 
bunch of NDs. First identified prion disease in human was Creutzfeldt-Jakob disease. It is 
found periodically and about one case per million individuals per year is observed. In the 
sane individuals, cellular isoform (PrPC) of prion protein exists two large alpha-helical 
structures. While in the pathogenic protease-resistant isoform (PrPSc), predominant β-sheet is 
found that may produce toxic amyloid aggregates. When a pathogenic isoform has been 
originated, PrPC modified into PrPSc via protein-protein interaction [134].
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5.1. Prion disease therapy
Many in-vitro studies showed that different types of polyamine dendrimers are 
retracting pathogenic prion isoform (PrPSc) from lysosomal degradation and eradicate them 
from infected cells. The different polyamines have positive charges over them and their 
action depend on this positive charge. Lim et al. synthesized less toxic positively charged 
polyamines with greater potential [135]. Ai Tran et al. synthesized polyelectrolyte multilayer-
coated Au NP containing sulfonates and primary amines as functional groups on the surface 
with a great therapeutic relevancy and inhibited to PrPSc aggregation in neuroblastoma cells 
at very low dose [136]. Sousa et al. [137] indicated that Au NP coated with the similar groups 
have crossing ability across the murine BBB and enter the specify neuronal structures in 
which PrP agglutination occurs. On the other side, McCarthy et al on the bases of 
dendrimer/prion interactions, formulated a new working model which indicated that 
dendrimers destabilize the prion protein and rendering it susceptibility to proteolysis thus 
eliminate PrP(Sc) [138]. In another study, it has been found that dendrimers inhibited the 
intracellular conversion of PrPC to PrPSc while anti-prion activity is independent from their 
cationic surface charges. This work indicate inhibitory action of mPPI G5 dendrimers against 
the conversion of PrPC to PrPSc and also determine the effect of other drugs which are 
enhancing this action of  mPPI G5 dendrimer [139].
5.2. Prion disease diagnosis
Xiao et al. developed a novel diagnostic approach, involving two different type of 
aptamers which were able to recognize various epitopes of PrPSc and segregate PrPSc from 
PrPc in serum as well as in brain homogenate [140]. In this approach, the aptamers were 
attached to the surface of QDs and magnetic micro particles, in presence of PrPSc. These 
produced a highly fluorescent sand which like structure in aqueous medium and it can be 
easily isolated under the influence of external magnetic field. Xie et al. demonstrated in-vitro 
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site-specific labeling of PrP expressed on cell surfaces from PEG-interspersed nitrile triacetic 
acid-functionalized QDs [141].
6. Nanotechnology for amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis (ALS) lead to fatal neurodegeneration and affect 
approximately 1-2/10,0000 person per year. The signet of this disorder includes paralysis of 
voluntary muscles from the selective death of motor neurons in the brain and spinal cord. The 
mutations in SOD1 gene which encode superoxide dismutase enzyme is the main cause of 
ALS in approx. 20% of familial ALS cases. The mutated SOD1 gene leads to formation of 
toxic free radicals and intracellular aggregates that restrict chaperone or proteasome activity, 
with consequent mis-folding and inadequate expulsion of manifold proteins [142].
For the specific treatment of ALS, Bondì et al. synthesized riluzole solid lipid NP 
with high drug loading capacity and a greater efficacy than free riluzole. The higher drug 
loading capability with greater carrying capacity of riluzole solid lipid NP into the brain with 
lower indiscriminate bio distribution in rats open an another route for the use of NP for ALS 
therapy [143].
Recently, a rat model of ALS detection involved administration of T cells labeled 
USPIO NP in the MRI technology. The study revealed an infiltration of CD4+ lymphocyte in 
the midbrain/interbrain, while CD8+ cells were more confined to the brainstem region [144]. 
Machtoub et al. for the detection of the pathological regions in ALS rat brain, injected USPIO 
NP conjugated with anti-CD4 antibodies from intravenous route [145].
7. Nanotechnology for neuroprotection and neuronal tissue regeneration
7.1. Neuroprotection
Most of the time, a higher level of reactive oxygen species is involved in CNS 
injuries. It has been observed that multiple radicals able to incorporate per-molecule similar 
as radical sponges, but  a delocalized π double bond system eradicate superoxide radicals 
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over the dis-mutation catalytic mechanism [146]. A study indicated that a trismalonic acid 
derivative of the fullerene C60 molecule (C3) is able  to raise the life span of mice about 
300%  while lacking mitochondrial manganese superoxide dismutase (MnSOD) [147]. On the 
other hand, cerium oxide NP (nanoceria) are established as neuroprotective agents lead to 
higher antioxidant properties and guard the cells from death due to oxidative stress shown in 
In-vitro experiments on isolated rat spinal cord neurons [148].
7.2. Neuronal tissue regeneration
The strategies for repair of damaged neuronal tissues involve the extracellular 
scaffolds which attached neuronal tissues and facilitate axonal growth. Neurotrophins (NT) 
and nanofibres (NF) have structural similarities with neuronal tissues, widely used as 
regenerative medicines. Jin et al. [149] recently synthesized a multi-walled carbon nano tube  
coated with electrospun poly (l-lactic acid-co-caprolactone) NF, indicated its potential for the 
prohibition of outgrowth of  neurite in in-vitro experiments. On the other side, NT/NF both 
are utilized as scaffold and carrier for neurotrophin delivery, thus are involved in promotion, 
proliferation and differentiation of neurons. In-vivo experiments indicated that the 
incorporating potential of NF for nerve growth factor lead to effective regeneration and 
promotion of sciatic nerve [150]. One another approach leads to synthesis of electrically 
conducting NT/NF scaffolds for the enhancement of the regenerative processes with the 
future aspect for potentiating brain circuit activity. Electrically conducting nano-scaffolds 
broadly used in electrical stimulation of nerve stem cells due to their low obstruction and 
high charge transfer abilities [151]. Lee et al. in a combined approach, synthesized PLGA NF 
with electrically conducting polypyrrole covering which in in-vitro experiments act with 
nerve growth factor and lead neurite formation and outgrowth [152].
8. Neurotoxicity of NM
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In spite of greater potential of NM in the field of biomedical, there is some possible 
toxic effect of NM also observed on CNS [49,137,153]. The available data indicated that 
various factors including shape, surface area, surface charge, size, chemical composition are 
responsible for toxicity of NM. At the latest, on the bases of surface chemistry (bare, \NH2 
or\COOH functionalized) SPIONs has been investigated in-vitro neurotoxicity of on human 
neuroblastoma cell line at both cellular and molecular levels. It has been observed from MTT 
assay that the bare SPIONs have greater toxicity than those coated SPIONs, due to their 
increased tendency for absorption capability to vitamins, amino acids, and ions, leading to 
changes in pH and composition in cells and cell medium. DNA micro array experiments 
manifested that SPIONs-COOH provoke the up regulation of oxidative stress-inducible genes 
[154].Various factors like size, shape (spheres, rods, and urchins)and surface coating (PEG or 
acetyl trimethyl ammonium bromide) of gold NP has been investigated via in-vitro and in-
vivo experiments in term of their neurotoxicity.
Positively charged Au NPs exhibited toxicity on microglia and neurons during in-
vitro experiments, independently of the shape. The intranasal administration of Au NPs 
during in-vivo experiments induced TLR-2 promoter activity and transient microglia 
activation in transgenic mice. The induction and the affinity depended on shape and surface 
of NP. Moreover, it has been observed that spheres, in particular 50 nm sized Au NPs 
indicated significantly great extent of cell interactions than rods [155].
For the investigation of neurotoxicity of commercially available NTs, PC12 cells are 
is commonly used in-vitro model for neuro toxicity studies. During an experiment, it has been 
observed that NTs decreased PC12 cell viability and mitochondrial membrane potential, 
dependent on time and dose while an increase in ROS production, the cell cycle arrest in the 
G2/M phase and the apoptotic rate depend only on the dose of NTs [156].
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Zhang et al. found that the exposure of  TiO2 NP lead morphological changes of 
cortex neurons and disturb the levels of monoamine neurotransmitter in the sub-brain areas 
[8,157]. At the beginning some NP, indicated promising features in therapy and diagnosis but 
simultaneously their toxicity in the in-vivo experiments limited their clinical use. In the case 
of QD and NTs, repeated in-vivo toxicity limited their future use at the level of in vitro 
diagnosis. Thus, the benefit-risk balance should be carefully evaluated for nano technological 
approaches promised for brain drug delivery and diagnostics.
8. Recent advancement in therapeutic strategies of neurodegenerative disorders
8.1. Cannabinoid therapeutics 
The classic hallmarks of the aged brain and neurodegenerative conditions involve 
abnormal protein accumulation, impaired lysosomal system, oxidative stress, excitotoxicity, 
and neuroinflammation [158]. The endocannabinoid system (ECS) has been emerged as a 
viable target for symptom alleviation or disease progression based on pharmacological 
modulation of endocannabinoid signaling, which involves both cannabinoid receptor-
dependent effects and cannabinoid receptor independent effects [159]. The cannabinoid 
receptor-dependent effects are (i) activation of cannabinoid type-1 (CB1) receptors to 
normalize glutamate homeostasis or to activate autophagy; (ii) activation of cannabinoid 
type-2 (CB2) receptors and peroxisome proliferator-activated receptor γ (PPARγ); (iii) 
modulation of G-protein receptor 55 (GPR55) to reduce local inflammatory events [160].
8.2. Human fetal neural stem cell therapy
Clinical trials using primary brain fetal tissue demonstrated the suitability of neural 
stem cell (NSC) therapy for neurodegenerative diseases. Based on supportive, preclinical 
proof-of-principle data, up to 21 somatic stem cell-based pilot trials have been developed for 
the treatment of ALS [161].  Immune-deficient models represent one of the elective 
experimental paradigms for the analysis of putative tumorigenicity of hNSC in vivo. Three of 
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those studies have used hNSC lines: NCT01640067, NCT01348451 and NCT01730716. 
Interestingly, all the studies confirmed no acceleration in the course of the disease; on the 
contrary some of the patients showed a transient improvement of motor functions and ALS-
FRS scale [162–164]. Although the data are encouraging, however this type of conclusions 
should be addressed more properly in larger phase II/III trial.
8.3. 3D human brain cell models for neurodegenerative diseases
Reason behind a high degree of failure in many recent clinical trials for
disease-modifying therapeutics is the difficulty of translating findings from animal-based cell 
models to human patients. The majority of non-animal neurodegenerative disease research 
has been conducted in 2 dimensional (2D) models of rodent neonatal neurons and glia. The 
human stem cell technologies combined with microfluidic technologies have opened the door 
to development of patient-derived 3D brain cell models with the advantage in providing a 
micro-physiological system more closely reflecting the in vivo brain environment,
and promote the interaction between different patient-derived brain cell-types. The new 
patient derived 3D brain cell systems will likely improve translational
outcomes for disease therapeutics [165].
9. Perspectives and conclusion
Nowadays, scientists are investigating molecular, cellular and circuit functions of the 
CNS for the identification of causes and the pathways involved in neurodegeneration. The 
nanotechnological approaches are very progressive from the last few years in the direction of 
diagnosis and treatment of neurodegenerative disorders. However, more endeavors will be 
required in this arena for the conversion of preclinical experiments to substantial clinical 
exercises.
This is an arduous challenge for researchers, to develop feasible, compatible and 
acceptable theranostic NM for neurodegenerative disorders. Currently used magnetic ones 
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indicated a successful candidature as theranostic due to their magnetic properties that may be 
utilized for MRI, tissue engineering and cell tracking, targeted drug and gene delivery 
systems. Recently, nanotechnology continuously working for development of novel tools 
which will emerge new insights in treatment and diagnosis of NDs.
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Figure captions:
Figure 1 (A) Graphical representation of theranostics system; (B) Current application of 
theranostics nanotechnology in pharmaceutical field.
Figure 2 (A) An insight of blood brain barrier (BBB); (B) Schematic representation of 
different transport pathways across the BBB [166].
Figure 3 Desired features of nanomaterials
Figure 4 Pictorial representation of treatment of neuro-diseases from nanomedicine
Table captions:
Table 1: Overview of various neuro-therapies and interventions for CNS disorders.
Table 2: Advantages of different NPs for the treatment of Alzheimer’s disorder.
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Table 1: Overview of various neuro-therapies and interventions for CNS disorders.
Disorder Type of 
Nanostructure
 Therapeutic 
Agents 
Mechanism of Action Reference
Polymeric 
nanoparticles
Poly(alkyl 
cyanoacrylate) 
and 
poly(lactic 
acid) NPs
 These engineered long-circulating NPs 
may have the ability to capture the toxic 
forms of the Aβ(1-42) peptide from the 
systemic circulation and potentially 
improve Alzheimer's disease condition 
through the proposed "sink effect".
[167]
Poly(propylene 
imine) (PPI) 
glycodendrimers
Electroneutral 
maltose shell
 Modify the total burden of β-amyloid [168]
Dendrimer  Lysine base Protect cells against Aβ-induced 
cytotoxicity and K+ channel modulation
[169]
Chitosan 
nanoparticles
Tacrine Release of drug from nanoparticles was 
diffusion-controlled
[170]
Alzheimer’s 
disease
Polymeric 
nanoparticle 
Curcumin Decreased levels of H2O2, increased 
glutathione (GSH) concentrations and 
create redox intracellular environment
[171]
Nanoparticles Curcumin Curcumin nanoparticles increase 
neuronal differentiation by activating 
the Wnt/β-catenin pathway, involved in 
regulation of neurogenesis
[172]
 Lactoferrin (Lf) 
conjugated 
polyethylene 
glycol-polylactide-
polyglycolide 
(PEG-PLGA) 
nanoparticle (Lf-
NP)
Urocortin Lf-NP effectively attenuated the 
striatum lesion 
[118]
Poly(ethylene 
glycol)–
poly(lactic-co-
glycolic acid) 
(PEG–PLGA) 
nanoparticles 
Urocortin 
peptide 
(UCN)
OL modification increased the brain 
delivery of nanoparticles and enhanced 
the therapeutic effects of UCN-loaded 
nanoparticles on Parkinson's disease
[117]
 Poly-L-lysine 
(DGL) 
dendrigraft/NPs
Gene 
encoding 
human glial 
cell line-
derived 
neurotrophic 
factor 
(hGDNF), 
DPA/hGDNF
Improved locomotor activity and 
apparent recovery of dopaminergic 
neurons
[173]
Dendrimers  L-DOPA DOPA dendrimers showed an increased 
aqueous solubility and enhanced 
photostability
[174]
Dendrimers Viologen-
phosphorus
Viologen-phosphorus dendrimers inhibit 
ASN fibril formation
[121]
Parkinson's 
disease
PAMAM G4 
dendrimer
PAMAM G4 
dendrimer
Increase in tyrosine residue 
fluorescence, and inhibited fibrillation 
of ASN
[119]
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Table 2: Advantages of different NPs for the treatment of Alzheimer’s Disorder
Type of 
nanoparticle
Therapeuti
c Agents
Preparation 
method
Advantages/ 
applications
Route of
administrati
on
Referenc
e
Polystyrene
nanoparticles
Metal
chelators
a) Copper
chelator
-D 
Penicillami
ne
Conjugation of 
drug and 
nanoparticles
Deliver D-
penicillamine to
the brain for the 
prevention
of Aβ (1–42) 
accumulation
[175]
Polystyrene
nanoparticles
b) Iron
chelator
— MAEHP
Polystyrene 
nanoparticles 
activated by
N-cyclohexyl-N_-
(2-morpholino 
ethyl)
carbodiimide 
methyl-p-
toluensulfonate
and then reacted 
with the iron
chelator, 2-methyl-
N-(2_-aminoethyl)-
3-hydroxyl-4-
pyridinone
Nanoparticle–
chelator conjugates
have the potential 
to inhibit Aβ
fibril formation and 
to cross the BBB 
and protect human 
brain cells from 
Aβ-related toxicity
[176]
Polymeric n-
butyl-
2-
cyanoacrylate
Quinoline
derivatives
— 
Clioquinol
Polymerization 
technique
Drug loaded 
nanoparticles 
exhibited
specificity for Aβ 
plaques both in 
vitro and in vivo; 
capable of aiding in 
the early diagnosis 
of AD
i.v. injection [177]
Chitosan 
nanoparticles
Hormones
— Estradiol
Prepared by ionic 
gelation of chitosan
with 
tripolyphosphate 
anions (TPP)
Chitosan 
nanoparticles 
significantly
increase the 
transport of 
estradiol into the
central nervous 
system
Intranasal
administratio
n
[178]
Poly (ethylene 
glycol)-poly
(lactic acid) 
nanoparticles
modified with 
wheat germ
Proteins 
and
peptides
—VIP
Produced by 
emulsion/solvent
evaporation 
technique
Improvement in 
brain delivery of 
estradiol
using wheat germ 
agglutinin 
nanoparticles
Intranasal
administratio
n
[179]
38
agglutinin
a) 
Polysorbate-
80
coated poly 
(nbutylcyanoa
crylate)
NP
ChEIs
—Tacrine
Enhanced 
concentration of 
the drug in the 
brain
i.v. injection [180]
Chitosan 
nanoparticles
ChEIs
—Tacrine
Spontaneous 
emulsification
method
A new drug 
delivery system for 
increasing
bioavailability of 
the drug in the 
brain
i.v. injection [170]
Core–shell 
nanoparticles
composed of a 
polystyrene
core and a 
degradable 
PBCA
[poly (butyl-
2-cyano 
acrylate)]
shell
Amyloid β
targeted
drugs
—
Thioflavin 
T
and S
Emulsion 
polymerization
method
Tools to trace and 
clear Aβ in the 
brain
Intracerebro 
ventricular
injections
[181]
Poly (n-butyl 
cyanoacrylate
)
Rivastigmi
ne
Emulsion 
polymerization
method
3.82 folds increase 
in brain 
concentration
of the drug
I.v. injection [182]
Viologen–
phosphorus 
dendrimers
Conjugation 
Method
Non-toxic
viologen–
phosphorus 
dendrimers 
inhibited the 
activities of both 
cholinesterases, 
showing their 
potential as new 
drugs for treating 
neurodegenerative 
diseases
[69]
Gold 
nanoparticle
Gold
nanoparticl
es
AuNPs were 
functionalized with 
peptide
H-Cys-Leu-Pro-
Phe-Phe-AspNH2 
(Cys-PEP) which 
was synthesized 
following a
Fmoc strategy and 
The prepared 
nanoparticles 
dissolve toxic
protein deposits of 
Aβ1–42 (amyloid
deposits) by the 
combined use of 
weak microwave 
fields and gold 
[183]
39
solid phase 
synthesis,
forming the 
conjugates AuNP–
Cys-PEP
nanoparticles
(AuNP) without 
any bulk heating
Eudragit S100 
nanocapsule
Melatonin Produced by 
interfacial 
deposition of
preformed polymer
Melatonin-loaded 
polysorbate 80-
coated 
nanocapsules 
caused a marked 
reduction on
lipid peroxidation 
levels and also 
increased the total 
antioxidant 
reactivity in the
hippocampus
Intraperitone
al
injection
[184]
Chitosan 
nanoparticles
Amyloid 
beta
Prepared by a 
combination of
mechanical stirring 
emulsification
methods and 
chemical 
crosslinking
method
Nano-vaccine 
delivery system 
could be used as a 
potential carrier for 
A beta
Systemic
administratio
n
[185]
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Figure 1 (A) Graphical representation of theranostics system; (B) Current application of 
theranostics nanotechnology in pharmaceutical field.
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Figure 2 (A) An insight of blood brain barrier (BBB); (B) Schematic representation of 
different transport pathways across the BBB [166].
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Figure 3 Desired features of nanomaterials
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Figure 4 Pictorial representation of treatment of neuro-diseases from nanomedicine
